Clinical Trials · NCT01916174
A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 50
- Start date
- Aug 2013
- Locations
- 1 site, Germany
- Primary endpoint
- Area under the serum IDeg concentration time curve after single dose